Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective SAJAC Study of Rehabilitation for Adolescents and Young Adults with Cancer in a Comprehensive Cancer Center.

Journal of adolescent and young adult oncology·2026
Same author

Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.

Breast (Edinburgh, Scotland)·2026
Same author

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
Same author

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA oncology·2026
Same author

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026
Same author

Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancer.

NPJ digital medicine·2026

Related Experiment Videos

[Her2 positive breast cancer: practices].

Mario Campone1, Dominique Berton-Rigaud, Emmanuelle Bourbouloux

  • 1Institut du cancer Nantes-Atlantiques, centre René-Gauducheau, Saint-Herblain, France. m-campone@nantes.fnclcc.fr

Bulletin Du Cancer
|May 19, 2011
PubMed
Summary

Molecular classification aids targeted therapies for breast cancer subtypes like HER2-positive. Trastuzumab and lapatinib are key HER2-targeted treatments, offering effective clinical options for physicians.

Related Experiment Videos

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Perou and Sørlie molecular classification system categorizes breast tumors into distinct subtypes.
  • This classification is crucial for tailoring effective targeted therapies.
  • HER2-positive breast cancer represents a significant subtype requiring specific treatment strategies.

Purpose of the Study:

  • To review and consolidate pertinent data on HER2-targeted therapies for breast cancer.
  • To provide physicians with readily accessible, useful information for daily clinical practice.
  • To highlight the role of molecular classification in optimizing treatment selection.

Main Methods:

  • Literature review of existing studies and clinical data.
  • Focus on therapies targeting the HER2 pathway in breast cancer.
  • Synthesis of information on trastuzumab and lapatinib efficacy and application.

Main Results:

  • Trastuzumab and lapatinib are established HER2-targeted therapies with proven clinical effectiveness.
  • Molecular subtyping, particularly identifying HER2-positive status, is essential for treatment selection.
  • Data supports the systematic use of these targeted agents in appropriate patient populations.

Conclusions:

  • Effective utilization of targeted therapies in breast cancer relies on accurate molecular classification.
  • Trastuzumab and lapatinib are vital treatment options for HER2-positive breast cancer.
  • This review offers a practical resource for clinicians managing HER2-positive breast cancer.